journal article·2026Open access

Bis-prodrug cryopreserved lipid nanoparticles with enzymatically triggered release

Cameron Hogarth, Keith Arnold, Heba Elkateb, Steve Rannard, Tom O. McDonald

Nanoscale Advances· Volume 8· Issue 3

Abstract

Lipid nanoparticle (LNP) formulations have emerged as a versatile platform for the delivery of therapeutics. However, achieving long-term stability and effective delivery of water-soluble small molecule drugs remains a challenge. In this study, we demonstrate a cryopreservable LNP formulation incorporating a hydrophobically modified bis-prodrug of lamivudine. By systematically varying the surfactant composition by combining a PEGylated surfactant (Brij S20) with an unPEGylated, zwitterionic lipid (Lipoid S100), we identify formulations that maintain colloidal stability following freeze-drying and redispersion in the presence of 10% w/v sucrose. Particle size measurements before and after lyophilisation indicate that surfactant ratio significantly impacts redispersibility, with 50/50 Brij/lipoid compositions offering the best performance. A core composition comprising the prodrug and tricaprin at either 1 : 1 or 3 : 1 ratio was evaluated, with the 3 : 1 formulation achieving redispersed particle sizes below 150 nm and low polydispersity. Enzymatic studies using porcine liver esterase confirm slow, sustained conversion of the bis-prodrug to active lamivudine over up to 9 weeks. This work highlights the opportunity of a prodrug-based strategy to formulate water-soluble APIs into stable, freeze-dried LNPs, enabling controlled, enzyme-responsive release. These findings offer insight into how surfactant composition influences freeze-drying compatibility and provide a platform for the development of LNP systems for small molecule delivery.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Lipid Membrane Structure and Behavior · Nanoparticle-Based Drug Delivery · Advancements in Transdermal Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, University of Liverpool, Crown Street, Liverpool, L69 7ZD, UK

Material Innovation Factory, University of Liverpool, Liverpool, L7 3NY, UK

Department of Materials, The University of Manchester, Oxford Road, Manchester, M13 9PL, UK

Henry Royce Institute, The University of Manchester, Oxford Road, Manchester, UK

Funding

Engineering and Physical Sciences Research Council

References (61)

Show source-provided references
1. Cullis · Nat. Rev. Drug Discovery · 2024 · 23 · 70910.1038/s41573-024-00977-6 ↗
2. Huang · Research · 2024 · 7 · 037010.34133/research.0370 ↗
3. Zong · Adv. Mater. · 2023 · 35 · 230326110.1002/adma.202303261 ↗
4. Saez · Int. J. Cosmet. Sci. · 2018 · 40 · 10310.1111/ics.12452 ↗
5. Fathi · Expert Opin. Drug Delivery · 2024 · 21 · 147910.1080/17425247.2024.2410951 ↗
6. John · Pharmaceutics · 2024 · 16 · 13110.3390/pharmaceutics16010131 ↗
7. Tang · Drug Discovery Today · 2018 · 23 · 115910.1016/j.drudis.2018.04.007 ↗
8. Long · J. Mater. Chem. B · 2025 · 13 · 229510.1039/D4TB02653E ↗
9. Karim · Arch. Pharmacal Res. · 2022 · 45 · 86510.1007/s12272-022-01418-x ↗
10. Li · J. Liposome Res. · 2025 · 35 · 7610.1080/08982104.2024.2378962 ↗
11. Schwarz · Int. J. Pharm. · 1997 · 157 · 17110.1016/S0378-5173(97)00222-6 ↗
12. Muramatsu · Mol. Ther. · 2022 · 30 · 194110.1016/j.ymthe.2022.02.001 ↗
13. Ball · Int. J. Nanomed. · 2017 · 12 · 30510.2147/IJN.S123062 ↗
14. Hermosilla · Vaccines · 2023 · 11 · 163510.3390/vaccines11111635 ↗
15. K. R.Ward and P.Matejtschuk , in Cryopreservation and Freeze-Drying Protocols , ed. W. F. Wolkers and H. Oldenhof , Springer US , New York, NY , 2021 , pp. 99–12710.1007/978-1-0716-0783-1_3 ↗
16. Luo · Eur. J. Pharm. Biopharm. · 2021 · 169 · 25610.1016/j.ejpb.2021.10.014 ↗
17. M.Yunus , Development of Lyophilization Cycle and Effect of Excipients on the Stability of Catalase During Lyophilization , https://jpionline.org/10.4103/2230-973x.93007/ , accessed November 11, 2024
18. Allison · Biochim. Biophys. Acta, Biomembr. · 2000 · 1468 · 12710.1016/S0005-2736(00)00251-0 ↗
19. Schersch · J. Pharm. Sci. · 2010 · 99 · 225610.1002/jps.22000 ↗
20. Sylvester · J. Pharm. Sci. · 2018 · 107 · 13910.1016/j.xphs.2017.05.024 ↗
21. Amis · Pharmaceutics · 2020 · 12 · 89210.3390/pharmaceutics12090892 ↗
22. Almalik · Saudi Pharm. J. · 2017 · 25 · 86110.1016/j.jsps.2016.12.008 ↗
23. Abdelwahed · Adv. Drug Delivery Rev. · 2006 · 58 · 168810.1016/j.addr.2006.09.017 ↗
24. Trenkenschuh · Int. J. Pharm. · 2021 · 606 · 12092910.1016/j.ijpharm.2021.120929 ↗
25. Muramatsu · Mol. Ther. · 2022 · 30 · 194110.1016/j.ymthe.2022.02.001 ↗
26. Kafetzis · Adv. Healthcare Mater. · 2023 · 12 · 220302210.1002/adhm.202203022 ↗
27. Ai · Cell Discovery · 2023 · 9 · 910.1038/s41421-022-00517-9 ↗
28. Kim · J. Controlled Release · 2023 · 353 · 24110.1016/j.jconrel.2022.11.022 ↗
29. Basso · Biomolecules · 2022 · 12 · 22310.3390/biom12020223 ↗
30. Elkateb · Int. J. Pharm. · 2020 · 588 · 11979410.1016/j.ijpharm.2020.119794 ↗
31. Kovačević · Int. J. Pharm. · 2020 · 576 · 11891810.1016/j.ijpharm.2019.118918 ↗
32. Hogarth · Nanoscale Adv. · 2024 · 6 · 66910.1039/D3NA00484H ↗
33. Elkateb · J. colloid interface sci. Open · 2023 · 11 · 100087
34. Taylor · Nanoscale Adv. · 2020 · 2 · 557210.1039/D0NA00582G ↗
35. Hogarth · J. Mater. Chem. B · 2021 · 9 · 987410.1039/D1TB02297K ↗
36. Hobson · Nat. Commun. · 2019 · 10 · 141310.1038/s41467-019-09354-z ↗
37. Zhang · Adv. Sci. · 2023 · 10 · 220524610.1002/advs.202205246 ↗
38. van der Meel · Small · 2021 · 17 · 210302510.1002/smll.202103025 ↗
39. Couvreur · Nat. Rev. Bioeng. · 2023 · 1 · 74910.1038/s44222-023-00082-0 ↗
40. Walther · Adv. Drug Delivery Rev. · 2017 · 118 · 6510.1016/j.addr.2017.06.013 ↗
41. Lentini · Bioorg. Med. Chem. Lett. · 2022 · 66 · 12872410.1016/j.bmcl.2022.128724 ↗
42. Quercia · JAIDS, J. Acquired Immune Defic. Syndr. · 2018 · 78 · 12510.1097/QAI.0000000000001660 ↗
43. Jiao · Small · 2024 · 20 · 230453410.1002/smll.202304534 ↗
44. Choi · Eur. J. Pharm. Biopharm. · 2008 · 68 · 54510.1016/j.ejpb.2007.07.011 ↗
45. Imran · J. Drug Delivery Sci. Technol. · 2022 · 77 · 10390410.1016/j.jddst.2022.103904 ↗
46. Schneck · Proc. Natl. Acad. Sci. U. S. A. · 2012 · 109 · 1440510.1073/pnas.1205811109 ↗
47. Van Eerdenbrugh · Int. J. Pharm. · 2007 · 338 · 19810.1016/j.ijpharm.2007.02.005 ↗
48. Din · Eur. J. Pharm. Biopharm. · 2015 · 94 · 6410.1016/j.ejpb.2015.04.019 ↗
49. Varshosaz · Pharm. Dev. Technol. · 2012 · 17 · 18710.3109/10837450.2010.529149 ↗
50. Esfandiary · J. Pharm. Sci. · 2016 · 105 · 142710.1016/j.xphs.2016.02.003 ↗
51. de Chasteigner · Drug Dev. Res. · 1996 · 38 · 11610.1002/(SICI)1098-2299(199606)38:2<116::AID-DDR6>3.0.CO;2-M ↗
52. Fonte · J. Controlled Release · 2016 · 225 · 7510.1016/j.jconrel.2016.01.034 ↗
53. Taylor · Nanoscale Adv. · 2023 · 5 · 187010.1039/D2NA00834C ↗
54. Shi · Nanoscale Adv. · 2022 · 4 · 95210.1039/D1NA00838B ↗
55. K.Taylor , K.Fritz , M. V.Pellegrini and M.Parmar , in StatPearls , StatPearls Publishing , Treasure Island (FL) , 2025
56. Perez · ChemMedChem · 2013 · 8 · 166210.1002/cmdc.201300255 ↗
57. Zheng · Angew. Chem., Int. Ed. · 2016 · 55 · 451410.1002/anie.201511244 ↗
58. Shervington · Molecules · 2022 · 27 · 295810.3390/molecules27092958 ↗
59. Hajizadeh · J. Iran. Chem. Soc. · 2022 · 19 · 157510.1007/s13738-021-02416-4 ↗
60. Yan · Biochim. Biophys. Acta, Mol. Basis Dis. · 1999 · 1454 · 18310.1016/S0925-4439(99)00035-6 ↗
61. Prakash · J. Chem. · 2008 · 5 · 125917